- Home
- MDT vs BMY Comparison
MDT vs BMY Comparison
Compare MDT & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDT | BMY |
|---|---|---|
| Founded | 1949 | 1887 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.0B | 113.5B |
| IPO Year | 2014 | 2006 |
Fundamental Metrics
Financial Performance| Metric | MDT | BMY |
|---|---|---|
| Price | $96.14 | $60.96 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 29 | 28 |
| Target Price | ★ $104.40 | $65.63 |
| AVG Volume (30 Days) | ★ 27.0M | 13.1M |
| Earning Date | 11-17-2026 | 10-29-2026 |
| Dividend Yield | 3.02% | ★ 4.16% |
| EPS Growth | 3.32 | ★ 178.46 |
| EPS | 1.14 | ★ 2.93 |
| Revenue | $36,364,000,000.00 | ★ $48,194,000,000.00 |
| Revenue This Year | $7.16 | $3.51 |
| Revenue Next Year | $3.64 | N/A |
| P/E Ratio | $84.39 | ★ $20.66 |
| Revenue Growth | ★ 8.43 | N/A |
| 52 Week Low | $73.31 | $42.52 |
| 52 Week High | $106.33 | $68.64 |
Technical Indicators
Market Signals| Indicator | MDT | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 67.88 | 48.00 |
| Support Level | $95.59 | $59.91 |
| Resistance Level | $105.50 | $61.45 |
| Average True Range (ATR) | 2.16 | 1.61 |
| MACD | 1.00 | 0.09 |
| Stochastic Oscillator | 94.15 | 59.11 |
Price Performance
Historical ComparisonAbout MDT Medtronic plc.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.